BioSpace News Archive

Business

Is AstraZeneca’s $80B Revenue Goal By 2030 a Bridge Too Far?

CEO Pascal Soriot on Tuesday heralded a “new era of growth” for AstraZeneca with plans to launch 20 new medicines in six years. He’s delivered before but can he do it again?

May 24, 2024
·
3 min read
·
Greg Slabodkin
Drug Development

Zealand Touts Phase I Results for GLP-1, GLP-2 Candidate Despite Modest Weight Loss

Aiming to compete in the lucrative weight-loss drug market, Zealand Pharma on Thursday posted topline results showing its dapiglutide led to only a slight weight reduction in low doses.

May 24, 2024
·
2 min read
·
Tyler Patchen
Drug Development

Lilly Invests Another $5.3B in Indiana Plant to Boost Tirzepatide Manufacturing

Amid shortages of its Mounjaro and Zepbound blockbuster drugs, Eli Lilly on Friday said it is investing an additional $5.3 billion in its production site in Lebanon, Indiana, to boost output of their active ingredient.

May 24, 2024
·
2 min read
·
Tyler Patchen